Insider Selling: TransMedics Group, Inc. (NASDAQ:TMDX) Insider Sells 2,960 Shares of Stock

TransMedics Group, Inc. (NASDAQ:TMDXGet Free Report) insider Tamer I. Khayal sold 2,960 shares of the stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $133.10, for a total transaction of $393,976.00. Following the sale, the insider now directly owns 20,843 shares of the company’s stock, valued at approximately $2,774,203.30. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

TransMedics Group Stock Performance

Shares of TransMedics Group stock opened at $133.02 on Friday. The business has a 50-day simple moving average of $112.42 and a 200 day simple moving average of $91.29. TransMedics Group, Inc. has a one year low of $36.42 and a one year high of $144.23. The company has a debt-to-equity ratio of 3.18, a current ratio of 9.72 and a quick ratio of 8.76. The firm has a market capitalization of $4.38 billion, a price-to-earnings ratio of -391.24 and a beta of 1.95.

TransMedics Group (NASDAQ:TMDXGet Free Report) last released its quarterly earnings data on Tuesday, April 30th. The company reported $0.35 EPS for the quarter, beating the consensus estimate of ($0.05) by $0.40. TransMedics Group had a positive return on equity of 7.95% and a negative net margin of 3.43%. The firm had revenue of $96.90 million during the quarter, compared to the consensus estimate of $83.78 million. During the same quarter in the previous year, the company posted ($0.08) earnings per share. The company’s quarterly revenue was up 132.9% on a year-over-year basis. On average, research analysts anticipate that TransMedics Group, Inc. will post 0.76 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of TMDX. Pitcairn Co. grew its holdings in shares of TransMedics Group by 1.5% during the first quarter. Pitcairn Co. now owns 5,378 shares of the company’s stock valued at $398,000 after buying an additional 78 shares during the last quarter. Harbour Capital Advisors LLC boosted its stake in TransMedics Group by 1.7% during the 4th quarter. Harbour Capital Advisors LLC now owns 8,371 shares of the company’s stock valued at $627,000 after purchasing an additional 140 shares during the last quarter. RiverPark Advisors LLC increased its holdings in TransMedics Group by 19.5% during the 4th quarter. RiverPark Advisors LLC now owns 1,319 shares of the company’s stock worth $104,000 after purchasing an additional 215 shares in the last quarter. First Horizon Advisors Inc. increased its holdings in TransMedics Group by 26.8% during the 4th quarter. First Horizon Advisors Inc. now owns 1,049 shares of the company’s stock worth $83,000 after purchasing an additional 222 shares in the last quarter. Finally, Park Avenue Securities LLC raised its stake in shares of TransMedics Group by 3.4% in the first quarter. Park Avenue Securities LLC now owns 11,374 shares of the company’s stock worth $841,000 after purchasing an additional 372 shares during the last quarter. Institutional investors and hedge funds own 99.67% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently commented on TMDX shares. Cantor Fitzgerald began coverage on shares of TransMedics Group in a research note on Thursday. They issued an “overweight” rating and a $161.00 price objective on the stock. Morgan Stanley upped their price target on shares of TransMedics Group from $75.00 to $95.00 and gave the company an “equal weight” rating in a research report on Wednesday, February 28th. Canaccord Genuity Group lifted their price objective on TransMedics Group from $102.00 to $117.00 and gave the stock a “buy” rating in a research report on Wednesday, May 1st. Oppenheimer upped their target price on TransMedics Group from $105.00 to $125.00 and gave the company an “outperform” rating in a research report on Wednesday, May 1st. Finally, Stephens initiated coverage on TransMedics Group in a research note on Tuesday. They set an “overweight” rating and a $151.00 target price for the company. One equities research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $128.25.

Read Our Latest Research Report on TransMedics Group

About TransMedics Group

(Get Free Report)

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.

Read More

Insider Buying and Selling by Quarter for TransMedics Group (NASDAQ:TMDX)

Receive News & Ratings for TransMedics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransMedics Group and related companies with MarketBeat.com's FREE daily email newsletter.